DMSA sahtekarlığı.

   Bugün bir üyemizin DMSA ile ilgili sorusu yıllar önceki "Cıva sahtekarlığı ve uygulanan çelasyon tedavisi"ile ilgili sahtekarlıkların hala ülkemizde devam ettiğini gösteriyor. 
Bilhassa Amerika'da çok yaygın olarak uygulalan bu sahtekarlık, alınan ciddi tedbirlerle önlenebilmiş ve 
uygulayan sahtekar doktorlara meslekten men cezaları verilmiştir. 
Bu DMSA testinin hiçbir güvenilir yanı yoktur. Hele 24 saatlik değilde ilk idrar alınırsa, üyemizde olduğu gibi 
dehşetengiz sonuclar çıkması kaçınılmazdır.
Aşağıda bu doktorlardan biri hakkındaki kanuni işlem anlatılmaktadır.
İngilizce bilmeyenler, bilen birisine okutsunlar. 

3.1 Patient A, a 39-year-old male, presented to Licensee on December 6, 2012 on referral from a naturopathic physician and an acupuncturist, with symptoms of shortness of breath, chest wall pain, irritability, fatigue and “brain fog.” Patient A suspected that he suffered from mercury toxicity and reported that he had been exposed to broken fluorescent light bulbs in the workplace between 2006 and 2009. Licensee conducted a physical examination and recommended that Patient A undergo 2, 3-Dimercapto-l-propanesulfonic acid (DMPS) challenge to test for heavy metal toxicity. Licensee followed the challenge test with dimercaptosuccinic acid (DMSA) chelation therapy to address mercury toxicity. Licensee had Patient A sign an informed consent form on December 13, 2012. Patient A returned to the clinic on January 7, 2013, reporting “brain fog” and lethargy after receiving DMSA chelation. Patient A next presented on March 5, 2013 reporting shortness of breath, abnormal pulmonary function and mental confusion. Licensee put Patient A on a daily course of DMSA. Licensee charted this as a 5-7-5 protocol with 500 mg daily accompanied with an intravenous (IV) infusion of mineral replacement. Licensee continued Patient A on repeated courses of DMSA chelation through March and April and 2013. Licensee failed to address Patient A’s complaint of abnormal pulmonary function and did not comment on Patient A’s history of smoking, and methamphetamine abuse. Licensee did not address Patient A’s psychiatric history, and failed to address or rule out either pulmonary or psychiatric issues before attributing Patient A’s symptoms to mercury toxicity. Licensee’s diagnosis of mercury toxicity and treatment with DMSA were not medically indicated. The American College of Medical Toxicology disapproves of the use of post-chelator challenge urinary metal testing in clinical practice.

Yazar	Mesaj Konu Arama Konu Seçenekleri Yanıt Yaz Yeni Konu Oluştur Konuyu Yazdır Çeviri Konu
Dr.KadirTugcu Üye Profili Özel Mesaj Yolla Üyenin Mesajlarını Bul Arkadaş Listeme Ekle Uzman Kayıt Tarihi: 14 Ağu 2008 Durum: Aktif Değil Puanlar: 120042	Mesaj Seçenekleri Yanıt Yaz Alıntı Dr.KadirTugcu Bu mesaj kurallara aykırıysa buradan yöneticileri bilgilendirebilirsiniz. Teşekkürler(0) Alıntı Cevapla Konu: DMSA sahtekarlığı. Gönderim Zamanı: 21 Eyl 2022 Saat 18:55
	Bugün bir üyemizin DMSA ile ilgili sorusu yıllar önceki "Cıva sahtekarlığı ve uygulanan çelasyon tedavisi" ile ilgili sahtekarlıkların hala ülkemizde devam ettiğini gösteriyor. Bilhassa Amerika'da çok yaygın olarak uygulalan bu sahtekarlık, alınan ciddi tedbirlerle önlenebilmiş ve uygulayan sahtekar doktorlara meslekten men cezaları verilmiştir. Bu DMSA testinin hiçbir güvenilir yanı yoktur. Hele 24 saatlik değilde ilk idrar alınırsa, üyemizde olduğu gibi dehşetengiz sonuclar çıkması kaçınılmazdır. Aşağıda bu doktorlardan biri hakkındaki kanuni işlem anlatılmaktadır. İngilizce bilmeyenler, bilen birisine okutsunlar. 3.1 Patient A, a 39-year-old male, presented to Licensee on December 6, 2012 on referral from a naturopathic physician and an acupuncturist, with symptoms of shortness of breath, chest wall pain, irritability, fatigue and “brain fog.” Patient A suspected that he suffered from mercury toxicity and reported that he had been exposed to broken fluorescent light bulbs in the workplace between 2006 and 2009. Licensee conducted a physical examination and recommended that Patient A undergo 2, 3-Dimercapto-l-propanesulfonic acid (DMPS) challenge to test for heavy metal toxicity. Licensee followed the challenge test with dimercaptosuccinic acid (DMSA) chelation therapy to address mercury toxicity. Licensee had Patient A sign an informed consent form on December 13, 2012. Patient A returned to the clinic on January 7, 2013, reporting “brain fog” and lethargy after receiving DMSA chelation. Patient A next presented on March 5, 2013 reporting shortness of breath, abnormal pulmonary function and mental confusion. Licensee put Patient A on a daily course of DMSA. Licensee charted this as a 5-7-5 protocol with 500 mg daily accompanied with an intravenous (IV) infusion of mineral replacement. Licensee continued Patient A on repeated courses of DMSA chelation through March and April and 2013. Licensee failed to address Patient A’s complaint of abnormal pulmonary function and did not comment on Patient A’s history of smoking, and methamphetamine abuse. Licensee did not address Patient A’s psychiatric history, and failed to address or rule out either pulmonary or psychiatric issues before attributing Patient A’s symptoms to mercury toxicity. Licensee’s diagnosis of mercury toxicity and treatment with DMSA were not medically indicated. The American College of Medical Toxicology disapproves of the use of post-chelator challenge urinary metal testing in clinical practice.